← Back to Search

Virus Vaccine

mRNA-1653 for Human Metapneumovirus and Human Parainfluenza Infection

Phase 1
Waitlist Available
Research Sponsored by ModernaTX, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is testing a new vaccine that helps the body fight off two types of respiratory viruses. It will be tested on healthy adults and young children who have been exposed to these viruses before. The vaccine works by teaching the body to recognize and combat these viruses.

Eligible Conditions
  • Human Metapneumovirus and Human Parainfluenza Infection

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: mRNA-1653, Adult participantsExperimental Treatment1 Intervention
Participants will receive 1 of 2 doses of mRNA-1653, administered via intramuscular injection, on Day 1 and Day 57.
Group II: mRNA-1653 Pediatric participantsExperimental Treatment1 Intervention
Participants will receive 1 of 2 possible doses of mRNA-1653, administered via intramuscular injection, on Day 1 and Day 57.
Group III: Placebo, Adult participantsPlacebo Group1 Intervention
Participants will receive mRNA-1653-matching placebo, administered via intramuscular injection, on Day 1 and Day 57.
Group IV: Placebo, Pediatric participantsPlacebo Group1 Intervention
Participants will receive mRNA-1653-matching placebo, administered via intramuscular injection, on Day 1 and Day 57.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
mRNA-1653
2017
Completed Phase 1
~180

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

ModernaTX, Inc.Lead Sponsor
111 Previous Clinical Trials
61,380,913 Total Patients Enrolled
1 Trials studying Human Metapneumovirus and Human Parainfluenza Infection
124 Patients Enrolled for Human Metapneumovirus and Human Parainfluenza Infection
~9 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top